Top Page
Legend Biotech
(NASDAQ:LEGN)
Legend Biotech (LEGN) vs. SPDR S&P 500 ETF (SPY)
Legend Biotech Business Overview & Revenue Model
Legend Biotech Key Performance Indicators (KPIs)
Reflects the sales performance of Carvykti, a key product, indicating its market acceptance and contribution to the company’s revenue growth.
The FlyLegend Biotech Earnings Call Summary
Legend Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 908.96M | 627.24M | 285.14M | 117.00M | 68.83M | 75.00M |
| Gross Profit | 550.40M | 392.66M | 140.93M | 51.64M | 68.83M | 75.00M |
| EBITDA | -183.33M | -113.16M | -477.87M | -416.54M | -392.38M | -298.16M |
| Net Income | -239.70M | -177.03M | -518.25M | -446.35M | -403.58M | -266.37M |
Balance Sheet | ||||||
| Total Assets | 1.71B | 1.67B | 1.85B | 1.33B | 1.12B | 722.09M |
| Cash, Cash Equivalents and Short-Term Investments | 992.59M | 1.12B | 1.31B | 1.03B | 882.39M | 506.07M |
| Total Debt | 410.24M | 350.60M | 328.67M | 284.53M | 122.97M | 3.70M |
| Total Liabilities | 701.69M | 629.61M | 597.24M | 586.65M | 353.52M | 122.27M |
| Stockholders Equity | 1.01B | 1.04B | 1.25B | 744.31M | 765.94M | 597.77M |
Cash Flow | ||||||
| Free Cash Flow | -188.68M | -158.14M | -416.00M | -223.56M | -243.87M | -253.29M |
| Operating Cash Flow | -170.07M | -144.03M | -393.28M | -201.28M | -198.47M | -223.00M |
| Investing Cash Flow | -16.73M | -850.54M | 92.79M | -77.09M | -194.98M | -24.17M |
| Financing Cash Flow | 14.00K | 5.70M | 791.49M | 377.98M | 626.66M | 618.88M |
Legend Biotech Technical Analysis
Legend Biotech Risk Analysis
Legend Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $10.91B | ― | -32.44% | ― | 106.27% | -43.90% | |
57 Neutral | $7.90B | -10.04 | ― | ― | 2609.26% | -17.08% | |
55 Neutral | $8.91B | -37.30 | -275.50% | ― | 65.83% | 28.50% | |
53 Neutral | $7.00B | -34.74 | -240.36% | ― | 54.92% | 28.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $4.38B | -17.28 | -22.60% | ― | 74.91% | 31.54% | |
44 Neutral | $9.50B | -39.56 | ― | ― | ― | 18.47% |
Legend Biotech Corporate Events
On January 12, 2026, Legend Biotech reported at the J.P. Morgan Healthcare Conference that its flagship multiple myeloma therapy CARVYKTI has now been used to treat more than 10,000 clinical and commercial patients, supported by a significant global rollout to 279 sites in 14 markets and the completion of a major expansion of its Raritan, New Jersey facility, which is now the largest cell therapy manufacturing plant in the United States and can support up to 10,000 patients annually. The company highlighted strong late-stage clinical data presented in December 2025 showing durable progression-free survival and benefits from earlier-line use, recent US and EU label updates adding overall survival advantage versus standard therapies, and progress across its broader pipeline, including first-in-human results from allogeneic candidate LUCAR-G39D, opening a new Philadelphia R&D center, and dosing a first patient with a dual CD20/CD19 in vivo CAR-T, while also signaling a shift toward financial inflection with expected CARVYKTI franchise profitability in 2025, anticipated company-wide operating profit in 2026 and roughly $1.0 billion in cash and time deposits as of September 30, 2025.
The most recent analyst rating on (LEGN) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
On December 6, 2025, Legend Biotech announced new data from the CARTITUDE studies at the ASH Annual Meeting, highlighting the long-term benefits of CARVYKTI® in treating relapsed/refractory multiple myeloma. The studies showed significant progression-free survival benefits, especially when used earlier in treatment. Additionally, first-in-human results for LUCAR-G39D in non-Hodgkin lymphoma demonstrated promising safety and efficacy. These findings reinforce Legend Biotech’s position in the cell therapy market and suggest potential improvements in patient outcomes.
The most recent analyst rating on (LEGN) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
On November 12, 2025, Legend Biotech reported its unaudited financial results for the third quarter of 2025, highlighting significant growth in CARVYKTI® sales, with net trade sales reaching approximately $524 million. The company also announced regulatory updates, including FDA and European Commission label updates for CARVYKTI® to reflect its overall survival benefit. Legend Biotech has treated over 9,000 patients to date and initiated commercial production at its Tech Lane facility in Belgium. Financially, the company reported a net loss of $39.7 million for the quarter, a significant improvement from the $125.3 million loss in the same period of 2024. The company holds approximately $1.0 billion in cash and equivalents, providing a financial runway beyond 2026, with expectations of achieving company-wide profitability in 2026.
The most recent analyst rating on (LEGN) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
On November 3, 2025, Legend Biotech announced its participation in the 67th American Society of Hematology Annual Meeting, where it will present research on CARVYKTI® and a novel therapy, Lucar-G39D. These presentations highlight the company’s ongoing innovation in cell therapy and its efforts to expand treatment options for multiple myeloma and B-cell non-Hodgkin lymphoma, potentially impacting clinical practices and patient outcomes.
The most recent analyst rating on (LEGN) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
On October 10, 2025, Legend Biotech announced that the U.S. FDA approved a label update for its CARVYKTI® CAR-T cell therapy to include overall survival data from the Phase 3 CARTITUDE-4 study. This update highlights a significant improvement in overall survival for patients with relapsed, refractory multiple myeloma compared to standard care. Additionally, the label now includes warnings about immune effector cell-associated enterocolitis and the reactivation of the John Cunningham virus, which can lead to serious complications, emphasizing the need for careful management by prescribing physicians.
The most recent analyst rating on (LEGN) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
On October 14, 2025, Legend Biotech announced that its product CARVYKTI® achieved approximately $524 million in net trade sales for the quarter ending September 30, 2025. This announcement highlights the product’s significant market performance, although the sales figures are preliminary and subject to further financial review. The impact on Legend Biotech’s operations and industry positioning is notable, as it underscores the company’s growing influence in the biotechnology sector.
The most recent analyst rating on (LEGN) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.